💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Aminocaproic Acid

CHEMBL1046 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
131.2 g/mol
LogP
-3.0
Phase
4

An antifibrinolytic drug that inhibits plasminogen activators and plasmin, thereby preventing the breakdown of blood clots that have already formed at sites of bleeding. It is used to control excessive bleeding in conditions where the body's clot-dissolving system is overactive, including after surgery and dental procedures in hemophilia patients.

Molekularmasse

131,1700 g/mol

LogP

-3,00

TPSA

63,30 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Pain Management Asthma Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Chronic Kidney Disease Hypertension Chronic Pain Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
NCCCCCC(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)

                

                

                

                    
                    

                        
Molecular Formula

                        
C6H13NO2

                    

                    
                    

                        
HBD / HBA

                        
2 / 3

                    

                    
                    

                        
Rotierbare Bindungen

                        
5

                    

                    
                    
                    

                        
Schwere Atome

                        
9

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
An antifibrinolytic drug that inhibits plasminogen activators and plasmin, thereby preventing the breakdown of blood clots that have already formed at sites of bleeding. It is used to control excessive bleeding in conditions where the body's clot-dissolving system is overactive, including after surgery and dental procedures in hemophilia patients.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Aminocaproic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1046.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 564.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.